Jpmorgan Chase & CO Regenxbio Inc. Transaction History

Jpmorgan Chase & CO

$1.51 Trillion
Q3 2025

A detailed history of Jpmorgan Chase & CO transactions in Regenxbio Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 4,037,248 shares of RGNX stock, worth $46.5 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

4,037,248

Previous 4,364,343 7.49%

Holding current value

$46.5 Million

Previous $31.2 Million 24.85%

% of portfolio

0.0%

Previous 0.0%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 07, 2025	SELL	$7.46 - $9.89 $2.44 Million - $3.23 Million	-327,095 Reduced 7.49%	4,037,248 $39 Million
Q1 2025 May 12, 2025	BUY	$5.92 - $8.7 $1.35 Million - $1.98 Million	227,826 Added 5.51%	4,364,343 $31.2 Million
Q4 2024 Feb 12, 2025	BUY	$7.23 - $11.56 $12 Million - $19.2 Million	1,659,206 Added 66.98%	4,136,517 $32 Million
Q3 2024 Dec 26, 2024	SELL	$10.49 - $14.39 $5.61 Million - $7.7 Million	-535,165 Reduced 17.76%	2,477,311 $26 Million
Q3 2024 Nov 08, 2024	SELL	$10.49 - $14.39 $5.61 Million - $7.7 Million	-535,165 Reduced 17.76%	2,477,311 $26 Million
Q2 2024 Dec 26, 2024	BUY	$11.51 - $21.53 $6.16 Million - $11.5 Million	535,165 Added 21.6%	3,012,476 $35.2 Million
Q2 2024 Aug 12, 2024	SELL	$11.51 - $21.53 $8.17 Million - $15.3 Million	-710,077 Reduced 19.08%	3,012,476 $35.2 Million
Q1 2024 Dec 26, 2024	BUY	$12.17 - $24.61 $15.2 Million - $30.6 Million	1,245,242 Added 50.27%	3,722,553 $78.4 Million
Q1 2024 May 10, 2024	SELL	$12.17 - $24.61 $2.64 Million - $5.34 Million	-216,996 Reduced 5.51%	3,722,553 $78.4 Million
Q4 2023 Dec 26, 2024	BUY	$12.89 - $20.82 $18.8 Million - $30.4 Million	1,462,238 Added 59.03%	3,939,549 $70.7 Million
Q4 2023 Feb 12, 2024	BUY	$12.89 - $20.82 $3.53 Million - $5.71 Million	274,185 Added 7.48%	3,939,549 $70.7 Million
Q3 2023 Nov 14, 2023	SELL	$16.46 - $19.99 $596,098 - $723,937	-36,215 Reduced 0.98%	3,665,364 $60.3 Million
Q2 2023 Aug 11, 2023	SELL	$17.23 - $21.71 $5.24 Million - $6.6 Million	-304,044 Reduced 7.59%	3,701,579 $74 Million
Q1 2023 May 18, 2023	BUY	$18.08 - $24.55 $889,789 - $1.21 Million	49,214 Added 1.24%	4,005,623 $75.7 Million
Q1 2023 May 11, 2023	BUY	$18.08 - $24.55 $2.93 Million - $3.98 Million	161,932 Added 4.27%	3,956,409 $74.8 Million
Q4 2022 Feb 13, 2023	SELL	$20.4 - $24.73 $5.31 Million - $6.43 Million	-260,178 Reduced 6.42%	3,794,477 $86.1 Million
Q3 2022 Nov 14, 2022	SELL	$22.29 - $35.04 $4.24 Million - $6.67 Million	-190,241 Reduced 4.48%	4,054,655 $107 Million
Q2 2022 Aug 11, 2022	SELL	$19.35 - $35.04 $9.28 Million - $16.8 Million	-479,797 Reduced 10.16%	4,244,896 $105 Million
Q1 2022 May 11, 2022	SELL	$24.62 - $34.31 $6.9 Million - $9.61 Million	-280,080 Reduced 5.6%	4,724,693 $157 Million
Q4 2021 Feb 10, 2022	BUY	$30.19 - $40.28 $26.1 Million - $34.8 Million	864,447 Added 20.88%	5,004,773 $164 Million
Q3 2021 Nov 12, 2021	BUY	$29.09 - $45.68 $120 Million - $189 Million	4,140,326 New	4,140,326 $174 Million

Others Institutions Holding RGNX

# of Institutions

189

Shares Held

44.3M

Call Options Held

138K

Put Options Held

117K

View Full List

About REGENXBIO Inc.

Ticker RGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,230,000
Market Cap $498M
Description
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprie...

More about RGNX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Regenxbio Inc. Transaction History